Skip to main content

Table 4 Kaplan–Meier survival analysis for the epigenetic signature in these three sets

From: Epigenetic signature predicts overall survival clear cell renal cell carcinoma

Variable Training set (n = 213) Testing set (n = 106) Entire set (n = 319)
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
All 13.0 (8.0–21.2) < 0.0001 4.1 (2.2–7.7) < 0.0001 7.2 (4.9–10.6) < 0.0001
Age (years)
 ≥ 65 7.6 (3.7–15.8) < 0.0001 2.9 (1.2–7.4) 0.0178 4.5 (2.5–8.0) < 0.0001
 < 65 16.8 (8.6–32.8) < 0.0001 5.4 (2.3–12.7) 0.0002 9.6 (5.7–16.3) < 0.0001
Gender
 Female 15.7 (6.8–36.4) < 0.0001 4.5 (1.2–16.6) 0.0071 9.3 (4.6–18.8) < 0.0001
 Male 12.1 (6.5–22.5) < 0.0001 4.0 (1.9–8.2) 0.0005 6.4 (4.0–11.2) < 0.0001
Pathological stage
 Stage I/II 10.4 (4.3–25.3) < 0.0001 0.4414 5.2 (2.4–11.4) < 0.0001
 Stage III/IV 10.7 (5.9–19.3) < 0.0001 2.5 (1.2–5.2) 0.0258 5.3 (3.3–8.3) < 0.0001
Histologic grade
 Grade I/II 10.6 (3.0–38.1) < 0.0001 0.5311 5.1 (1.9–13.8) < 0.0001
 Grade III/IV 10.1 (5.8–17.8) < 0.0001 3.9 (2.0–7.9) 0.0007 6.1 (3.9–6.4) < 0.0001
Lymph node metastasis
 Positive 0.0048 0.5651 3.3 (1.4–7.4) 0.0222
 Negative 12.2 (7.1–21.0) < 0.0001 5.5 (2.5–12.3) < 0.0001 8.6 (5.5–13.5) < 0.0001